SecBot SecBot
SECBOTREPLAY Home › Report › RARE

RARE · Ultragenyx reported Q1 2026 revenue of $136M (consensus $158.4M) and…

Ultragenyx Pharmaceutical Inc. · PRESS-RELEASE filed May 5, 2026 at 16:01 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed May 5, 2026 at 16:01 ET

Ultragenyx reported Q1 2026 revenue of $136M (consensus $158.4M) and EPS of -$1.84 (consensus -$1.46), both missing expectations. Despite reaffirming full-year 2026 guidance of $730M-$760M revenue, the weak quarter and wider operating loss of $305M signal near-term headwinds, though upcoming PDUFA dates for DTX401 and UX111 provide potential catalysts.

  • Q1 2026 revenue $136M, down 2.2% YoY from $139M, missing consensus $158.4M
  • Q1 2026 EPS -$1.84 vs consensus -$1.46; net loss $185M vs $151M YoY
  • Reaffirmed full-year 2026 revenue guidance $730M-$760M and expense guidance
  • R&D expenses $187M, up from $166M YoY; SG&A $88M flat

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access